Gilead Sciences (GILD) Tops Q1 EPS by 48c, Raises FY Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. MSFT
6. NVDA
7. SPY
8. SKYD
9. RCKT
10. IBM

Go back to Gilead Sciences (GILD) Tops Q1 EPS by 48c, Raises FY Revenue Guidance

Gilead Sciences Announces First Quarter 2015 Financial Results

April 30, 2015 4:02 PM EDT

- ~90,000 U.S. and EU Patients Initiated Treatment on Sovaldi or Harvoni -

- Product Sales of $7.4 billion -

- Non-GAAP EPS of $2.94 per share -

- Revised 2015 Full Year Guidance -

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31, 2015. The financial results that follow represent a year over year comparison of first quarter 2015 to the first quarter 2014. Total revenues were $7.6... More